RetroSense Therapeutics, a biotechnology company dedicated to developing gene therapy approaches to vision restoration, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. patent application (No. 12,299,574), which broadly covers methods of restoring visual responses with a variety of optogenetic compounds.
The latest staffing, leadership and boardroom news from Michigan’s technology-focused companies, institutions and groups
RetroSense Therapeutics, a gene therapy company dedicated to vision restoration, announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research division of the FDA that took place on May 22 regarding RetroSense’s lead product candidate, RST-001 for vision restoration in retinal degenerative conditions.
The latest staffing, leadership and boardroom news from Michigan’s technology-focused companies, institutions and groups.
RetroSense Therapeutics LLC, a Michigan-based company, announced that it has executed its exclusive, worldwide option and signed a license agreement for novel gene-therapy approaches for treating blindness developed at Wayne State University’s School of Medicine.